In this issue:
Humoral and T cell immune responses to SARS-CoV-2 vaccination in MS patients on anti-CD20 therapy
Safety and efficacy of bexarotene in relapsing-remitting MS
Safety and efficacy of tolebrutinib in relapsing MS
Fatigue as the limiting factor for vaginal birth in MS patients
Prognostic accuracy of NEDA-3 in long-term outcomes of MS
Efficacy and safety of temelimab in MS
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in MS
Brain atrophy rates in patients with MS on long term natalizumab
Home infusions of natalizumab for people with MS
Ocrelizumab EID in MS
Please login below to download this issue (PDF)